Trial Profile
A phase Ib/II study of CBT-501 in combination of CG200745 in multiple solid tumors with high unmet medical needs
Status:
Planning
Phase of Trial:
Phase I/II
Latest Information Update: 26 Apr 2018
Price :
$35
*
At a glance
- Drugs Geptanolimab (Primary) ; Ivaltinostat (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 26 Apr 2018 New trial record
- 23 Apr 2018 According to a CBT Pharmaceuticals media release, this study may expects to initiate by the end of 2018.